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Abstract: Background: Biologic drugs have revolutionised the management of many inflammatory conditions. 
Patent expirations have stimulated development of highly similar but non-identical molecules, the biosimilars. 
Extrapolation of indications is a key concept in the development of biosimilars. However, this has been met with 
concerns around mechanisms of action, equivalence in efficacy and immunogenicity, which are reviewed in this 
article. 
Methods: Narrative overview composed from literature search and the authors’ experience. Literature search 
included Pubmed, Web of Science, and online document archives of the Food and Drug Administration and 
European Medicines Agency. 
Results: The concepts of biosimilarity and extrapolation of indications are revisited. Concerns around extrapola-
tion are exemplified using the biosimilar infliximab, CT-P13, focusing on mechanisms of action, immunogenicity 
and trial design. The opportunities and cautions for using biologics and biosimilars in unlicensed inflammatory 
conditions are reviewed. 
Conclusions: Biosimilars offer many potential opportunities in improving treatment access and increasing treat-
ment options. The high cost associated with marketing approval means that many bio-originators may never be-
come licenced for rarer inflammatory conditions, despite clinical efficacy. Biosimilars, with lower acquisition cost, 
may improve access for off-label use of biologics in the management of these patients. They may also provide opportu-
nities to explore off-label treatment of conditions where biologic therapy is less established. However, this poten-
tial advantage must be balanced with the awareness that off-label prescribing can potentially expose patients to 
risky and ineffective treatments. Post-marketing surveillance is critical to developing long-term evidence to pro-
vide assurances on efficacy as well as safety. 
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1. INTRODUCTION 
 Biologic drugs have revolutionised the management of many 
immune-mediated inflammatory conditions ranging from rheuma-
toid arthritis (RA) to inflammatory bowel disease (IBD). These 
drugs are extremely effective, yet also carry high acquisition costs. 
In the case of rheumatic diseases, they heralded the development of 
a market for high cost drugs, previously considered impossible and, 
in parallel, identified inflammatory diseases as attractive conditions 
for Industry to invest in [1]. The limited lifespan of patents for these 
drugs has stimulated programmes, many starting over a decade ago, 
to develop similar molecules that, whilst not identical to the origi-
nator, could be considered to be biological equivalent of a “ge-
neric”. Such “biosimilars” are defined as a biological agents that are 
similar in terms of quality, safety and efficacy to an already li-
censed reference product [2]. To help drive down cost, regulators 
such as the European Medicines Agency (EMA) and the US Food 
and Drugs Administration (FDA) have allowed biosimilars to fol-
low an expedited process for approval. Such a process can vastly 
reduce development costs, which can be passed on to healthcare 
systems as lower drug cost. Though as a compromise, they are not 
as extensively investigated as the reference product not only in 
gaining their licence (of crucial interest to biosimilar companies) 
but also in post-marketing evaluation for new indications (typically 
considered not cost-effective for major investment from Industry). 
This article reviews extrapolation of biosimilar indications and  
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explores the issues and opportunities presented by biosimilars with 
a focus on off-label use. 
2. BIOSIMILARITY AND EXTRAPOLATION OF INDICA-
TIONS 
 The prototype class of anti-inflammatory biologic are the anti-
tumour necrosis factors (TNF). Both etanercept (a fusion protein 
comprising two human p75 monoclonal TNF receptors, coupled to 
a human IgG1 Fc tail) and the monoclonal anti-TNF antibodies 
(infliximab, adalimumab, golimumab and the PEGylated certolizu-
mab) are large, mainly protein, molecules. They are produced by 
recombinant DNA techniques using a single clone of cells through 
a highly refined process. In the manufacturing process, primary 
amino-acid sequences undergo post-translational modifications 
such as sialyation, that are affected by the cell line and their envi-
ronment [3]. This creates specific protein-folding and complex 
three dimensional structures. Each manufacturer uses a unique cell 
line and production process, therefore copies cannot be identical to 
the reference product (RP) [4]. In fact, no two batches of any bio-
logic, even the RP, can be identical [5]. 
 For each marketed indication, approval for the RP relies on 
clinical trials to demonstrate efficacy, safety and immunogenicity. 
In contrast, biosimilar approval does not require the manufacturer 
to re-establish efficacy, but is instead based on the demonstration 
that there are no clinically meaningful differences from the RP. 
This involves comprehensive comparison firstly of structure and 
function through complex analytical and in vitro studies, then in 
vivo animal studies and, finally, abridged clinical studies of phar-
macokinetics, pharmacodynamics, immunogenicity, safety and 
efficacy [2, 6, 7]. 
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 Once biosimilarity has been established in one indication, the 
drug may be approved for additional indications held by the RP 
without comparative clinical trials. Extrapolation of indication is 
integral to the concept of biosimilarity. It reduces the number and 
size of clinical trials required, thereby decreasing financial cost and, 
potentially, increasing access [7]. It is however worth noting that 
the dramatic cost reductions and improved access for small-
molecule generics were due to automatic substitution at the phar-
macy level [8]. This is not currently the case for biosimilars in most 
regions. Full “interchangeability” requires additional standards that 
are currently lacking, as each biosimilar is compared only to the 
RP, without any evaluation of potential swapping between two or 
more biosimilars for the same RP. 
Table 1. Approval status of proposed biosimilars of infliximab, etanercept, adalimumab, and rituximab, as of November 2017. 
 	   Biosimilar	   EMA approval status	   FDA approval status	  
CT-P13	   Remsima/Inflectra 	  
Approved Sept 2013	  
Inflectra	  
Approved Apr 2016	  
SB2	   Flixabi	  
Approved May 2016	  
Renflexis	  
Approved Apr 2017	  
PF-06438179	   NS	   N/A	  
BOW015	   NS	   NS	  
Infliximab	  
ABP710	   NS	   NS	  
ABP501	   Solymbic	  
Approved Jan 2017	  
Amjevita	  
Approved Sept 2016	  
BI 695501	   Cyltezo	  
Approved Nov 2017	  
Cyltezo	  
Approved Aug 2017	  
SB5	   Imraldi	  
Approved Jun 2017	  
NS	  
CHS-1420	   NS	   NS	  
GP2017	   NS	   NS	  
M923	   NS	   NS	  
BCD-057	   NS	   NS	  
Adalimumab	  
PF-06410293	   NS	   NS	  
SB4	   Benepali	  
Approved Jan 2016	  
NS	  
GP2015	   Erelzi	  
Approved Jun 2017	  
Erelzi 	  
Approved Aug 2016	  
CHS-0214	   NS	   NS	  
HD203	   NS	   NS	  
LBEC0101	   NS	   NS	  
Etanercept	  
ENIA11 (TuNEX)	   NS	   NS	  
CT-P10	   Truxima	  
Approved Dec 2016	  
NS	  
GP2013	   Rixathon	  
Approved Jun 2017	  
NS	  
ABP798	   NS	   NS	  
PF-05280586	   NS	   NS	  
Rituximab	  
BCD-020	   NS	   NS	  
NS, not submitted; N/A, not applicable.	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 The concept of biosimilar extrapolation is not new. Regulation 
was less complex for biosimilar recombinant human protein ana-
logues, such as epoetin and filgrastim, where each mechanism of 
action is mediated by the same receptor [9]. In contrast, mAbs are 
much more complex molecules; comprising Fab and Fc regions, 
each with considerable diversity and variable mechanisms of action. 
The Fab region can neutralise soluble TNF (sTNF) and remove 
them from the immune pathway. They can also bind to transmem-
brane TNF (tmTNF) and activate intracellular signalling resulting 
in apoptosis or cytokine suppression [10, 11]. The Fc region has the 
ability to bind to specific receptors, leading to potential effector 
functions such as antibody-dependent cellular cytotoxicity, com-
plement-dependent cytotoxicity, and antibody-dependent cellular 
phagocytosis. Binding to the neonatal Fc receptor (FcRn) also pro-
tects the mAb from proteolytic degradation [12].  
3. CONCERNS AROUND EXTRAPOLATION 
 The biosimilar infliximab CT-P13 was the first to be licensed in 
the US and EU (see Table 1 for other biosimilars). Comprehensive 
comparative analyses were supported by two clinical trials demon-
strating that pharmacokinetics (PK), efficacy, safety and immuno-
genicity were comparable in ankylosing spondylitis (AS) and RA 
[13-16]. Extension studies also demonstrated unaffected safety, 
efficacy and immunogenicity when switched from the RP [17, 18]. 
In the US and EU, CT-P13 indication was then extrapolated to all 
RP indications for psoriasis, psoriatic arthritis, Crohn’s disease and 
ulcerative colitis [19, 20]. This was however met with much con-
troversy for several reasons. 
 Although TNF may play a pivotal role in the immune pathway 
of all six disease indications, it is clear that various mechanisms of 
action are not of equal importance in each condition. Reverse sig-
nalling via tmTNF binding is thought to be an important mecha-
nism of action in IBD [11]. This is supported by the fact that etan-
ercept, which binds less avidly to tmTNF, is effective in rheumatic 
indications but not in IBD [21]. Another mechanism of action 
thought to be relevant in IBD is natural killer (NK) cell induced 
target cell lysis, although this had been contested [22, 23]. Com-
pared to its RP, CT-P13 had reduced binding to NK cell FcγRIIIa 
(low affinity immunoglobulin γ Fc region receptor IIIa) and for this 
reason was not approved for IBD in Canada [24]. 
 Concern around immunogenicity is another suggested reason to 
limit extrapolation, as anti-drug antibodies (ADAs) can affect safety 
and efficacy [25]. For example, a minor change in the manufactur-
ing process of epoetin was thought to have caused autoantibodies to 
endogenous erythropoietin and the dramatically increased incidence 
of pure red cell aplasia - a rare but potentially fatal condition [26]. 
Similarly, infliximab ADA positive Crohn’s patients were much 
more likely to experience infusion reactions [27]. 
 Comparing immunogenicity is difficult, for example ADA was 
reported in up to 61% in Crohn’s disease [27], but varied signifi-
cantly depending on concomitant medication [28]. However, there 
do seem to be situations where the frequency of ADAs differs from 
one disease to another, possibly due to the immunological back-
ground underlying the inflammatory process. For example, around 
48% of RA patients developed ADAs to infliximab at 30 weeks, 
compared with 23-27% of AS patients [13, 15]. 
 Lastly, there were concerns around having RA as the disease 
model to demonstrate comparability between CT-P13 and the RP. 
Unlike biomarker endpoints used in biosimilar studies of recombi-
nant human protein analogues, mAb trials rely on less sensitive 
clinical outcomes due to their complex mechanisms of action. A 
large treatment-placebo effect difference is therefore necessary to 
reliably demonstrate equivalence. Of the six infliximab indications, 
RA was associated with one of the smallest placebo-adjusted re-
sponse [29, 30]. It may therefore not be the most sensitive clinical 
model to detect a potential difference in efficacy between CT-P13 
and its RP. Similarly for immunogenicity, the population with the 
highest immune response should be used to provide the best sensi-
tivity in detecting differences [31]. RA studies reported less in-
fliximab ADA development [30, 32] compared with Crohn’s dis-
ease [27] or psoriasis [33]. In summary, the RA studies of efficacy 
and immunogenicity equivalence did not exclude the possibility 
that CT-P13 and its RP are different in extrapolated indications, 
where differences may be more easily detected. Experts therefore 
argued that dedicated clinical trials were needed for each indication 
and many clinicians hesitated to use biosimilars even when regula-
tory approval for extrapolation was granted [34-36]. It was only 
with subsequent real world data and confirmatory studies that prac-
tice began to change [37, 38]. This highlights the need to have addi-
tional post-market monitoring to develop long-term evidence to 
provide assurances on efficacy as well as safety. 
4. OPPORTUNITIES FROM BIOSIMILARS 
 Controversies aside, the dawn of biosimilar mAbs presents 
many potential opportunities as a result of their reduced cost [39]. 
The most obvious is the hope to increase drug access or to reinvest 
savings for other health resources. Take for example biosimilar 
filgrastim (a granulocyte colony-stimulating factor) which was 
launched in late 2008. With their reduced cost, funding agencies in 
the UK updated guidelines which saw use of both RP and biosimi-
lar filgrastim increase by over 100% in the subsequent six years 
[40]. A significant number of these patients may not have otherwise 
received the drug.  
 In 2008, the then named National Institute for Clinical Excel-
lence (NICE) rejected RP infliximab for AS on the grounds of cost-
effectiveness [41]. The cost of biosimilar infliximab and its impact 
on the RP cost, meant that in 2016 NICE reissued guidance that 
recommended infliximab if the patient is started on the least expen-
sive product [42]. This increased access to TNF inhibition therapy, 
and also increased the number of treatment options for these pa-
tients. 
 For IBD, the UK Royal College of Physicians’ annual audit of 
biologics suggested that the introduction of biosimilar infliximab 
could half the annual cost of treatment [43]. This would save the 
health services an estimated £90 million per year if all patients were 
switched to a biosimilar [44]. The 2016 audit, which captured the 
introduction of biosimilar infliximab in 2015, reported the largest 
annual increase in the absolute number of biologic-treated patients; 
22% of patients were prescribed biosimilar infliximab [45]. In addi-
tion to licenced indications, biosimilars may also improve access to 
biologics for other unlicensed inflammatory conditions. 
5. OFF-LABEL USE OF BIOSIMILARS 
 Many of the issues of biosimilars discussed so far have focused 
on considerations of regulatory agencies. However, these agencies 
do not have authority over the use of drugs outside of their licensed 
indications. Health care professionals can prescribe drugs “off-
label” to treat (typically rare) conditions other than those formally 
approved. There are several reasons why off-label prescribing exists 
[46]. The most pertinent, in the case of biologics, is related to their 
cost. 
 For any biologic, obtaining approval for a new indication re-
quires extensive and costly clinical studies. In the US, licence ap-
proval requires two randomised, placebo-controlled clinical trials 
that demonstrate both efficacy and safety in the disease for which 
the indication is being sought [47]. If a disease is uncommon, such 
trials will be difficult to conduct and, even if approved, the revenue 
may not offset costs in obtaining approval. Consequently, there are 
many inflammatory diseases which share common pathological 
pathways but may never receive licence as an indication. Of course, 
biosimilar development and usage may be very different in Asia 
and the third world countries, where regulatory requirements for 
biosimilar approval vary and are less stringent. 
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 There are many instances where biologics  have been successful in 
treating unlicensed inflammatory diseases [48]. Indeed some off-label 
uses are integral to disease management and recommended in 
guidelines. For example infliximab for Behçet’s disease [49] or 
rituximab in refractory lupus, lupus nephritis [50, 51] and ANCA asso-
ciated vasculitis (AAV) [52, 53]. Greater accessibility to biologics 
may improve management of patients with such unlicensed indica-
tions. For example in AAV, rituximab is non-inferior to cyclophos-
phamide for remission induction [54, 55] with preferable qualities 
with respect to fertility and infection concerns. However, the cost-
effectiveness of rituximab had been raised as a concern [56]. The 
emergence of rituximab biosimilars will undoubtedly improve care 
for patients with AAV or other conditions where rituximab is as 
effective as cyclophosphamide. 
 Reduced biologic costs may also promote further controlled 
trials to generate higher quality evidence, such as for inflammatory 
myositis [57]. Additionally, more opportunities may open up to 
explore off-label treatment of conditions where biologic therapy is 
less established, such as TNF inhibition for polymyalgia rheumatica 
[58] or giant cell arteritis [59, 60]. However, it is worth noting that 
biosimilar manufacturers will be unlikely to seek approval for addi-
tional indications. Once licensed, a biosimilar needs to go through 
the same approval process as the RP for additional indications. If 
the RP were to obtain new indications, extrapolation of indications 
in the biosimilar no longer applies. 
 There is concern that if a drug can be used off-label, patients 
have less incentive to enrol in trials where they may receive a pla-
cebo. This may reduce opportunity to develop rigorous data and 
could explain why most off-label studies are anecdotal reports [48]. 
Most importantly, unregulated off-label prescribing can potentially 
expose patients to risky and ineffective treatments [61]. Therefore 
off-label use must be applied with the same level of caution as for 
the RP [62]. Post-market monitoring is essential to develop long-
term evidence and provide assurances on efficacy as well as safety. 
6. PHARMACOVIGILANCE 
 Given the nature of biologics and their production, the model 
used for drug safety monitoring of small-molecule generics is in-
adequate. Pharmacovigilance systems need to be able to distinguish 
between adverse events associated with the biosimilar from those of 
its RP. Therefore, the UK’s Medicines and Healthcare products 
Regulatory Agency (MHRA) recommends that all biologics, in-
cluding biosimilars, are prescribed by brand name rather than Inter-
national Non-proprietary Name [63, 64]. 
 As with all new medicines, biosimilars have a 'black triangle' 
for usually two years post-approval to encourage reporting of sus-
pected adverse drug reactions (ADR). The MHRA's Yellow Card 
scheme in the UK requires such reports to provide the brand name 
and batch number to aid traceability [65]. This information should 
also be provided to patients to help more accurate reporting. In the 
US, similar post-approval safety surveillance is performed using 
voluntary reporting systems. There is also a system of active sur-
veillance using retrospective analysis of medical records and drug 
event monitoring using patient surveys [66]. 
 The EMA also recommends that all biosimilar manufactures 
should participate in existing pharmacoepidemiological studies, 
such as registries that have been set up primarily to monitor safety 
[67]. The British Society for Rheumatology (BSR) recommends 
that all patients using biosimilars should be registered with the BSR 
biologics register [68]. 
CONCLUSION 
 The emergence of biosimilars heralds an exciting time for the 
management of inflammatory diseases. Extrapolation of indication 
is integral to the concept of biosimilar development. The conse-
quent cost reductions will improve access, increase treatment op-
tions, and help resource reallocation to research in hitherto low 
volume but high-impact diseases. The use of biosimilars should, 
however, be approached with similar levels of caution as with their 
RP and robust mechanisms should be in place for efficacy assess-
ments and pharmacovigilance. 
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